Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 14 (3), 143-9

Update on Chemoprevention of Prostate Cancer


Update on Chemoprevention of Prostate Cancer

Eric A Klein et al. Curr Opin Urol.


Purpose of review: Prostate cancer remains the most commonly diagnosed visceral cancer in men in the United States, with almost 200,000 newly diagnosed cases in 2003. Prevention of this disease would have a major impact on disease-associated cost, morbidity, and mortality for a large segment of the population. A major advance in prevention of prostate cancer came in 2003 with the publication of the Prostate Cancer Prevention Trial. This overview summarizes the results of that trial, the design of other large-scale trials, and advances in understanding of the molecular mechanisms underlying the effect of other promising agents.

Recent findings: The Prostate Cancer Prevention Trial demonstrated that use of finasteride is associated with a 25% reduction in the 7-year period prevalence of prostate cancer in men over age 55 years with normal digital rectal exam and initial prostate specific antigen <3.0 ng/ml. Use of finasteride was associated with a slightly higher risk of Gleason sum 7-10 tumors, some sexual side effects, and fewer urinary symptoms. A substantial body of new molecular evidence supports the existing body of clinical and epidemiological data leading to testing of vitamin E and selenium as preventative agents in men at risk for prostate cancer. Epidemiologic and molecular evidence also makes cyclooxygenase-2 inhibitors, lycopene, soy, and green tea promising agents.

Summary: Results of a population-based, randomized phase III trial demonstrates that finasteride can prevent prostate cancer. A large amount of data supports the use of other agents as potential preventatives, including selenium, vitamin E, vitamin D, other 5-alpha-reductase inhibitors, cyclooxygenase-2 inhibitors, lycopene, and green tea. Some of these agents are being tested in new large-scale phase III clinical trials.

Similar articles

  • Update on Prostate Cancer Chemoprevention
    JF Lowe et al. Pharmacotherapy 26 (3), 353-9. PMID 16503715. - Review
    Data regarding lycopene, vitamin E, and selenium as chemoprevention for prostate cancer appear promising. Prospective trials such as the Selenium and Vitamin E Cancer Pre …
  • The Future of Prostate Cancer Prevention
    OW Brawley et al. Ann N Y Acad Sci 952, 145-52. PMID 11795434. - Review
    The dramatic international variation in prostate cancer mortality rates suggest an environmental influence. This combined with a building understanding of the genetic mec …
  • SELECT: The Selenium and Vitamin E Cancer Prevention Trial
    EA Klein et al. Urol Oncol 21 (1), 59-65. PMID 12684129. - Review
    SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.
  • Chemoprevention of Prostate Cancer: The Prostate Cancer Prevention Trial
    IM Thompson et al. Prostate 33 (3), 217-21. PMID 9365551. - Clinical Trial
    While the primary objective of this study is to determine whether finasteride can reduce the period prevalence of prostate cancer over a 7-year period, the biologic and d …
  • [Prostate Cancer Chemoprevention]
    R Krysiak et al. Przegl Lek 62 (9), 929-33. PMID 16541732. - Review
    Prostatic cancer is the most common malignancy diagnosed in men. Chemoprevention of prostatic cancer is a relatively new concept and seems to be a very promising strategy …
See all similar articles

Cited by 20 PubMed Central articles

See all "Cited by" articles